Bristol Myers Squibb (BMY) debt: $44.8B
Bristol Myers Squibb had $44.8B of long-term debt on Dec 31, 2025, including the part due within a year, down 9.3% from $49.4B a year earlier.
From Bristol Myers Squibb's filings with the SEC · Read the filing · BMY stock page
Bristol Myers Squibb debt by year
#33 of 2,129 US companies by debt · See the full ranking
| Year ended | Debt | Change |
|---|---|---|
| Dec 31, 2025 | $44.8B | -9% |
| Dec 31, 2024 | $49.4B | +25% |
| Dec 31, 2023 | $39.5B | +1% |
| Dec 31, 2022 | $39B | -12% |
| Dec 31, 2021 | $44.4B | – |
Debt of similar companies
Companies in the same industry as Bristol Myers Squibb, by SEC industry code, with the closest debt. Each name opens the same page for that company.
| Company | Debt, latest year | Year ended |
|---|---|---|
| Pfizer | $64.6B | Dec 31, 2025 |
| AbbVie | $64.5B | Dec 31, 2025 |
| Merck | $49B | Dec 31, 2025 |
| Bristol Myers Squibb | $44.8B | Dec 31, 2025 |
| Johnson & Johnson | $41.4B | Dec 28, 2025 |
| Eli Lilly | $40.9B | Dec 31, 2025 |
| Bausch Health Companies | $20.8B | Dec 31, 2025 |
Questions and answers
What is Bristol Myers Squibb's debt?
Bristol Myers Squibb had $44.8B of long-term debt on Dec 31, 2025, including the part due within a year, down 9.3% from $49.4B a year earlier.
Numbers as reported in Bristol Myers Squibb's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology